Company: BLRX
Filing Date: 2025-03-31
Form Type: 20-F
Source: 0001178913-25-001123
Chunk: 329

Company: BioLineRx Ltd.
Filing Date: 2025-03-31
Form: 20-F
Item: Item 19
Chunk 329
---
 16, 2022.  

  (18)      Incorporated by reference to the Registrant’s Form 6-K filed on August 30, 2023.  

  (19)      Incorporated by reference to the Registrant’s Annual Report on Form 20-F filed on March 26, 2024.  

  (20)      Incorporated by reference to the Registrant’s Form 6-K filed on April 1, 2024.  

  (21)      Incorporated by reference to the Registrant’s Form 6-K filed on November 21, 2024.  

  (22)      Incorporated by reference to the Registrant’s Form 6-K filed on January 7, 2025.  

SIGNATURES

The Registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this annual report on its behalf.

  BIOLINERX LTD.                               
  By:                 /s/ Philip A. Serlin     
                      Philip A. Serlin         
                      Chief Executive Officer  

Date: March 31, 2025

BioLineRx Ltd.

INDEX TO FINANCIAL STATEMENTS:

                                                                                                                                   Page  
  REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM (PCAOB name: Kesselman & Kesselman C. P. A.s and PCAOB ID No. 1309)      F-2   
  CONSOLIDATED FINANCIAL STATEMENTS:                                                                                                     
  CONSOLIDATED STATEMENTS OF FINANCIAL POSITION                                                                                    F-4   
  CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS                                                                                    F-5   
  CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY                                                                                     F-6   
  CONSOLIDATED STATEMENTS OF CASH FLOWS                                                                                            F-7   
  NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS                                                                                   F-9   

Report of Independent Registered Public Accounting Firm

To the Board of Directors and Shareholders of BioLineRx Ltd.

Opinion on the Financial Statements

We have audited the accompanying consolidated statements of financial position of BioLineRx Ltd. and its subsidiaries (the “ Company”) as of December 31, 2024 and 2023, and the related consolidated statements of comprehensive loss, changes in equity and cash flows for each of the three years in the period ended December 31, 2024, including the related notes (collectively